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Abstract
Developing a non-hormonal male contraceptive requires identifying and characterizing an 
appropriate target and demonstrating its essential role in reproduction. Here we review the 
development of male contraceptive targets and the current therapeutic agents under consideration. 
In addition, the development of EPPIN as a target for contraception is reviewed. EPPIN is a well 
characterized surface protein on human spermatozoa that has an essential function in primate 
reproduction. EPPIN is discussed as an example of target development, testing in non-human 
primates, and the search for small organic compounds that mimic contraceptive antibodies; 
binding EPPIN and blocking sperm motility. Although many hurdles remain before the success of 
a non-hormonal male contraceptive, continued persistence should yield a marketable product.
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1. Introduction
Male contraception began with the use of the condom and dates to ancient times in Imperial 
Rome (Youssef, 1993). Today the condom is still in use and is one of only two methods 
available to men, aside from early withdrawal, which is always problematic. Vasectomy for 
contraception, the second method available, is a more recent invention that was initially for 
criminals and other degenerates (Ochsner, 1899, 1925). Today these two methods persist; 
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men still have two choices for contraception, the condom and vasectomy. Perhaps it is time 
for something new?
During the early years of the 20th century human reproduction was not well understood and 
research progress in reproduction awaited the discovery and mechanistic understanding of 
human hormones. When the effects of progesterone on ovulation were reported in 1937 
(Makepeace, Weinestein & Friedman, 1937) the stage was set for the research and 
developmental efforts that led to the FDA approval of Enovid in 1957, for infertility and 
menstrual irregularities, and by 1960 as a birth control pill (Eig, 2014). The marketing of 
Enovid by G.D. Searle & Co., which evolved into the modern birth control “pill”, focused 
the interest of the pharmaceutical industry, and indeed much of academic research in 
reproduction, on understanding hormonal regulation of the reproductive system. 
Reproductive endocrinologists had a target and a ligand to study.
2. Male Contraception
Research work on male contraception began with a search for easy targets specific to the 
male aiming to disrupt sperm or testis function. In the context of the success of the female 
“pill” the most obvious choice was a hormonal approach in which testosterone or its 
analogues were used to inhibit testicular steroidogenesis as a means to block 
spermatogenesis. Non-hormonal targets for contraception however, were not obvious and 
much more difficult to define. Early workers (Landsteiner, 1899; Henle, Henle, & 
Chambers, 1938; Tyler, 1948) interested in identifying and studying the function of sperm 
proteins (antigens) utilized the immunogenicity of spermatozoa and the specificity of the 
resulting antisera (Tyler, 1961) as probes for function (O’Rand & Metz, 1974); with the 
hope of finding a contraceptive target. Spermatogenesis, a highly ordered process that 
occurs inside the protection of the blood-testis barrier (Waites & Setchell, 1969; Dym & 
Fawcett, 1970; Vitale, Fawcett, & Dym, 1973), presented an abundance of male specific 
proteins that might become targets for contraception (O’Rand & Romrell, 1977). With the 
realization that infertility patients often had anti-sperm antibodies (Rümke & Hellinga, 
1959), the idea developed that sperm proteins synthesized in the testis, might be the basis for 
the development of a contraceptive. This in turn led to early attempts to find sperm proteins 
(antigens) that would serve as contraceptives in women (Munoz & Metz, 1978; Metz, 1978; 
Morton & McAnulty, 1979). Finding contraceptives for men on the other hand, did not 
generate any scientific interest aside from studies in guinea pigs and humans, whose focus 
was on the concerns of developing autoimmune orchitis as a result of male contraception 
(Mancini, 1976).
In the 1970s and 1980s interest in developing contraceptives for men focused largely on the 
study of plant extracts known to affect fertility. Extracts of Justicia gendarussa (Prajogo 
EW et al., 2009) and Tripterygium wilfordii (Zhen, Ye, & Wei, 1995), as well as gossypol 
(Liu, Lyle & Cao 1987a, and 1987b), an extract of cottonseed, all have been studied as 
possible male contraceptives. Unfortunately plant extracts by their very nature suffer from a 
lack of specificity and attempts at purification and synthesis of the “active” ingredient have 
often presented unacceptable toxicology profiles or led to irreversible infertility.
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In spite of progress in identifying sperm protein structure and function, understanding the 
functional significance of these male targets had to await advances in molecular biology and 
its associated technologies. Most notably the advent of mouse “knockout” technology 
allowed the function of a protein to be studied by disrupting the expression of its gene. One 
of the first knockouts to disrupt reproduction related functions was the estrogen receptor 
gene, affecting both male and female fertility (Lubahn et al., 1993). Studies disrupting male 
specific genes demonstrated that loss of function of testis or epididymal specific proteins 
could lead to male-specific infertility (Sonnenberg-Riethmacher, Walter, Riethmacher, 
Gödecke, & Birchmeier, 1996; Dix et al., 1996; Kastner et al., 1996). Removing a specific 
gene from expression in the testis or epididymis with subsequent fertility testing allowed a 
very specific conclusion; namely that the removed protein was essential for fertility. For 
example the targeted disruption (“knockout”) of the CatSper gene (Ren et al., 2001) during 
spermatogenesis and therefore in developing spermatozoa demonstrated the essential 
function of calcium channels in sperm motility and mouse fertility. The recently developed 
CRISPR (clustered regularly interspaced short palindromic repeat)-CAS technology may 
allow further refinement of gene manipulation to target testis or sperm specific proteins 
(Archambeault & Matzuk, 2014).
3. Milestones
Today any identification and characterization of a contraceptive candidate must include a 
demonstration of essential function in fertility. Consequently a list of critical questions or 
milestones can be developed for putative contraceptive targets that follow from the 
demonstration of essential function. Is the function specific to the testis, the epididymis, or 
spermatozoa? For example one could imagine the function being transmembrane ion 
currents (e.g. Breton, Smith, Lui & Brown, 1996; Kirichok, Navarro & Clapham, 2006), an 
enzyme activity, (e.g. GAPDHS (Miki et al., 2004); LDH-C4 (Odet et al., 2008)), a protein-
protein binding event (O’Rand et al., 2004), a transmembrane receptor signaling (Gottwald, 
Davies, Fritsch, & Habenicht, 2006; White et al, 2013), or a protein-nucleic acid binding 
event (Matzuk et al., 2012). Having identified an essential function, can it be blocked 
reversibly? Drugs such as ion channel blockers, receptor antagonists and enzyme inhibitors 
immediately come to mind. The next question is: Can an assay be established to measure the 
effects of blocking the target’s function on fertility? To answer this question, establishing a 
phenotypic assay is a crucial milestone because it enables the search for a therapeutic agent 
to specifically and reversibly block the function. Finally the putative contraceptive target 
needs to be understood at a molecular level, to have the mechanism of action characterized 
such that future investors in the technology are convinced of the specificity and reversibility.
4. Current Pharmacologic Prospects
Although there is no shortage of putative contraceptive targets for men, the actual number 
under development has been limited because of the availability of funding and the necessity 
of meeting the required milestones. Luckily a number of therapeutic agents have been 
identified while being tested for other applications. For example lonidamine drugs were first 
anticancer therapeutics but their derivatives became Adjudin (Cheng et al., 2002; Cheng et 
al., 2005) and Gamendazole (Tash et al., 2008; Tash, Attardi, et al., 2008a), both of which 
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disrupt spermatogenesis by interference with Sertoli cell function. The indenopyridines, 
particularly l-CDB-4022 (originally RTI-4587-073 from RTI in Research Triangle Park, 
NC), have been tested for contraceptive effectiveness, and in non-human primates the 
disruption of Sertoli cell function proved to be reversible (Hild, Reel, Dykstra, Mann, & 
Marshall, 2007). The disruption of Sertoli cell function, particularly with Gamendazole, 
which has been studied in some detail (Tash et al., 2008, 2008a), brings into focus a number 
of important questions related to the contraceptive milestones discussed above. 1) What is 
the mechanism of action and is it specific to the testis? If Gamendazole only affects a subset 
of functions of HSP90AB1 and EEF1A1 as reported (Tash et al., 2008a), how will this 
affect the therapeutic window over long time courses of administration? This is worrying 
because in rats 3 mg/kg (single oral dose) results in complete recovery but not complete 
infertility while 6 mg/kg results in 100% infertility but only 57% recovery (Tash et al., 
2008). The window is rather narrow for complete inhibition of spermatogenesis and 
reversibility. 2) What are the long term effects of disrupting the apical ectoplasmic 
specializations in Sertoli cells over several months or years? Daily treatment with 6 mg/kg 
Gamendazole during 7 days further reduced fertility recovery to 29% (Tash et al., 2008); 
further suggesting that longer treatment with this drug may render males sterile. 3) Would 
autoimmune orchitis eventually develop as a result of the immune system’s exposure to 
sluffed off spermatids? 4) Perhaps of a more general concern when Sertoli cells are 
disrupted, what is the actual effect on male hormones? In vivo serum levels of inhibin B fall 
below measurable levels, which in turn affects FSH (Tash et al., 2008a); is this really a 
hormonal contraceptive? Until a more favorable toxicology profile can be demonstrated, 
testing in non-human primates seems premature. Whether these and other therapeutics that 
act on the disruption of Sertoli cell function and in particular Sertoli-germ cell junctions can 
be developed into marketable drugs remains to be seen (Boekelheide, Johnson, & Richburg, 
2005).
A more recent and most promising therapeutic agent for male contraception was reported by 
the Matzuk and Bradner laboratories in 2012 (Matzuk et al., 2012), utilizing the anti-cancer 
agent JQ1, which targets bromodomain (BRD) containing proteins. The testis specific form 
(BRDT) would meet target specificity, drugability and essential function requirements. 
What remains is the non-trivial task of translation from mice to men. If this exciting new 
therapeutic can specifically target BRDT in humans then male contraception will have made 
a significant advance. Since the human genome encodes several BRD containing proteins, 
such as BRD2, BRD3 and BRD4 (Berkovits & Wolgemuth, 2013; Sanchez & Zhou, 2009), 
the development of highly selective BRDT ligands will be important to avoid potential side 
effects due to inhibition of its somatic isoforms. Additional therapeutic agents, discovered in 
the late twentieth century have recently been re-investigated; including WIN 18,446 (Amory 
et al., 2011) which inhibits ALDH1a2 that converts vitamin A into retinoic acid. Although 
treatment with WIN 18,446 completely stops spermatogenesis and appears reversible given 
sufficient time, there should be serious concern with systemic effects that WIN 18,466 may 
have on obesity and lipidosis (Paik et al., 2014). BMS-189453 (Chung et al., 2011), which 
inhibits retinoic acid receptors from binding retinoic acid, has been shown to inhibit 
spermatogenesis through its effect on spermatids and the eventual loss of germ cells. As 
discussed above, the long term effects on Sertoli cells and the possibility of autoimmune 
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orchitis need to be considered. Two additional antagonists, BMS-189532 and BMS-195614, 
which have effects in in vitro assays, have been tested in vivo for their effects on 
spermatogenesis and found to have no effect (Chung et al., 2013); pointing out the 
importance of drug design and in vivo testing. While these studies are encouraging it 
remains to be determined whether drugs that disrupt spermatogenesis can avoid targeting 
stem cells or Leydig cell function, and can be administered over long time periods without 
cumulative off target side effects. A contraceptive that disrupts spermatogenesis will 
necessitate long pre-contraceptive and post-contraceptive wait times as at least 72 days are 
required for spermatogonia to differentiate and reach the cauda epididymides as mature 
spermatozoa. An approximate 90 day wait period to achieve the full contraceptive 
effectiveness may not appeal to some men and could increase the risks of failure and 
decrease therapeutic compliance.
Recent advancements in our understanding of sperm physiology, including calcium channels 
and metabolism (CatSper: Kirichok, Navarro, & Clapham, 2006; Lishko et al., 2012; 
GAPDHS: Miki et al., 2004; LDH-C4: Odet et al., 2008), have brought spermatozoa back 
into consideration as putative contraceptive targets. However, the downside of many sperm-
specific proteins is that they are only slight variations of somatic proteins. This creates a 
difficult situation in which that “slight variation” must be exploited to make the drug sperm 
specific. The study of protein-protein interactions on the surface of ejaculate spermatozoa 
expanded the scope of sperm targets for male contraception (Wang, Widgren, 
Sivashanmugam, O’Rand, & Richardson, 2005; Wang, Widgren, Richardson, & O’Rand, 
2007). If specific inhibitors for these sperm functions can be demonstrated for human 
spermatozoa then they would represent a new class of therapeutic agents that would not 
require disruption of spermatogenesis. Moreover they could be applied to spermatozoa in 
either males or females giving them a distinct advantage over other contraceptive agents. 
Thus, exploring sperm-surface targets for male contraceptive drug development has the 
potential to promote innovation in the field.
5. Development of EPPIN as a Contraceptive Target
As advantageous as “knockout” experiments are in mice, some reproductive functions in 
primates are not modeled particularly well in rodents. These reproductive functions 
generally involve maturation, secretory products in the male reproductive tract, and 
migration in the female tract. Genes with roles in innate immunity and reproduction evolve 
rapidly by positive Darwinian selection; particularly those associated with the male 
reproductive tract (Silva, Hamil, & O’Rand, 2013; Torgerson, Kulathinal, & Singh, 2002; 
Torgerson & Singh, 2003; Wyckoff, Wang, & Wu, 2000). EPPIN (epididymal protease 
inhibitor) is an example of a gene in the WFDC gene family whose evolution in the primate 
lineage has been rapid, driven by sexual function and sperm competition (Ferreira et al., 
2013). Our studies on EPPIN and its interacting partner semenogelin (SEMG1) are a recent 
case in point. The adaptive molecular coevolution of SEMG1 and EPPIN in primates may 
have rapidly changed their biochemical properties resulting in a gain of function for both 
proteins (Silva, Hamil, & O’Rand, 2013). For these reasons anti-sperm antibodies, studied 
for the last sixty years, still may provide tools for discovering the function of sperm specific 
molecules and whether or not they have essential roles in fertility. This is particularly true in 
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primates where creation of a null mutation is not practical. Therefore one strategy for the 
development of new contraceptives is to utilize immunization of non-human primates with 
specific sperm surface proteins and determine the effects of the immune response on the 
ejaculated spermatozoa of immunized males.
Human EPPIN is a single copy gene on chromosome 20 containing six exons that span 7 kb, 
whose protein contains 133 amino acids and whose expression is androgen dependent 
(Richardson et al., 2001; O’Rand, Widgren, Hamil, Silva, & Richardson, 2011). We utilized 
the immunocontraceptive approach to demonstrate that EPPIN has an essential function in 
reproduction. O’Rand et al., (2004) demonstrated effective and reversible contraception in 
male monkeys if a high serum anti-EPPIN titer (>1:1000) was maintained. The key 
observation in this study was that sperm motility and EPPIN-SEMG1 binding were inhibited 
by anti-EPPIN antibodies. In seminal plasma and on human spermatozoa following 
ejaculation, EPPIN was bound to SEMG1 (Wang, Widgren, Sivashanmugam, O’Rand, & 
Richardson, 2005; O’Rand, Widgren, Wang, & Richardson, 2006) and further studies led to 
the demonstration that the C-terminal domain of the EPPIN protein contained the critical 
epitope for both SEMG1 and anti-EPPIN antibody binding (O’Rand, Widgren, Beyler, & 
Richardson, 2009; O’Rand, Widgren, Hamil, Silva, & Richardson, 2011).
We now know that EPPIN has at least three physiological functions. Exhibiting strong 
antibacterial activity (Yenugu et al., 2004) and modulating the proteolytic activity of PSA 
(prostate specific antigen, a serine protease) against its seminal plasma substrate, SEMG1 
(Wang et al., 2007), are two functions that serve to protect spermatozoa from bacterial and 
proteolytic attack during transit in the female reproductive tract (O’Rand, Widgren, Hamil, 
Silva, & Richardson, 2011), as well as to modulate PSA activity on SEMG1 bound to 
EPPIN. Furthermore, EPPIN inhibits sperm motility when it binds SEMG1 on the sperm 
surface (Mitra, Richardson, & O’Rand, 2010). This third physiological function acts as an 
additional layer of protection in the female reproductive tract by preventing premature 
hyperactivation and capacitation. The effect of SEMG1 bound to EPPIN on the sperm 
surface manifests itself as a rapid decrease in internal pH (within less than 1 minute) and a 
decrease in internal calcium levels (>30% decrease with 3μM SEMG1; O’Rand & Widgren, 
2012). Thus the normal cascade of physiological events leading to fertilization, namely an 
increase in internal sperm pH which is necessary to activate the CatSper calcium channel 
which in turn is necessary for hyperactivation and fertility, is disrupted.
Our rational for selecting EPPIN as a contraceptive target is that it meets our milestones for 
an ideal contraceptive target: It is specific to the male reproductive system and has an 
essential function on ejaculate spermatozoa. Its function can be reversibly blocked with easy 
access to the target on the sperm surface. We have established assays to measure its function 
(see below) and we have determined its mechanism of action. The selection of EPPIN as a 
target overcomes any safety concerns regarding targeting spermatogenesis.
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6. Development of a Therapeutic Agent to selectively and reversibly 
Modulate EPPIN’s Function
EPPIN is a male-specific protein found on the surface of human spermatozoa that is 
essential for fertility in primates. The development of an anti-EPPIN immunocontraceptive, 
however, is not considered a viable commercial option for a number of reasons including 
individual efficacy. Therefore we have developed a series of small organic compounds that 
mimic the effect of anti-EPPIN antibodies binding to the sperm surface, thereby inhibiting 
sperm motility. As noted above, one of the milestones in developing a male contraceptive is 
developing an assay to block the essential function. For EPPIN we adapted the AlphaScreen 
assay (amplified luminescent proximity homogeneous assay, PerkinElmer, Waltham, MA) 
to look for “hit” compounds that would bind EPPIN and inhibit either anti-EPPIN antibody 
or SEMG1 from binding to EPPIN (Silva, Hamil, Richardson, & O’Rand, 2012; O’Rand, 
Widgren, Hamil, Silva, & Richardson, 2011). As described previously (O’Rand, Widgren, 
Hamil, Silva, & Richardson, 2011), in our primary compound screen we utilize histidine 
tagged recombinant human EPPIN attached to NTA-donor beads and anti-EPPIN antibody 
(S21C; against the EPPIN C-terminal domain) attached to protein A-acceptor beads. In our 
secondary compound screen we utilize donor beads that bind biotinylated SEMG1 and 
acceptor beads that bind EPPIN via anti-EPPIN (N-terminal) antibodies and protein A-
acceptor beads. This assay allows SEMG1 to bind to its EPPIN binding site on the C-
terminal of the EPPIN protein (O’Rand, Widgren, Hamil, Silva, & Richardson, 2011). As a 
control compound screen we use a Modified TruHits Assay (PerkinElmer) for non-specific 
bead binding and compound interference with the assay. Promising lead compounds were 
synthesized and tested for their ability to inhibit human sperm motility (O’Rand, Widgren, 
Hamil, Silva, & Richardson, 2011). In this live cell compound screen we established a 
computer-assisted sperm analysis (CASA) for determining the effect of compounds on 
human sperm motility (Silva, Hamil, & O’Rand, 2013). Additionally, to facilitate the IC50 
evaluation of compounds using different ejaculates and to reduce inter-assay variation due to 
differences in sperm quality in different semen samples, an index of relative motility 
inhibition (RMI) was developed. This is calculated as: RMI = [%motility*VSL]; percentage 
of motile sperm (%motility) multiplied by the straight-line velocity (VSL); the average 
velocity measured in a straight line from the beginning to the end of a sperm track in μm/sec 
as measured by CASA. Structures with IC50s <100μM in the anti-EPPIN (primary 
compound screen) and sperm motility assays (live cell compound screen) were considered 
further by examining their ability to dock into an EPPIN C-terminal 3D model described 
previously (Silva, Hamil, Richardson, & O’Rand, 2012).
7. Optimizing the Lead Compound
To optimize our lead compounds we characterized SEMG1’s binding to EPPIN in order to 
determine which EPPIN amino acid residues were important for sperm motility inhibition. 
Using recombinant human SEMG1 fragments and testing each for the inhibition of sperm 
motility, we found that the SEMG1 sequence E229-Q247 (E2Q) was the minimal sequence 
necessary to inhibit human sperm motility (Silva, Hamil & O’Rand, 2013). This E2Q 
sequence (229-E1HS3SKVQ7TS9LC11PAHQDKLQ19-247) was subsequently modeled in 
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PEP-FOLD (Shen, Maupetit, Derreumaux, & Tufféry, 2014; Thévenet et al., 2012; 
Maupetit, Derreumaux, & Tuffery, 2009; Maupetit, Derreumaux, & Tufféry, 2010) to 
produce a 3D peptide model which was subsequently modeled in ClusPro2 (Kozakov et al., 
2013; Kozakov, Brenke, Comeau, & Vajda, 2006; Comeau, Gatchell, Vajda, & Camacho, 
2004) to produce a series of structural models to predict the docking of the E2Q peptide into 
EPPIN’s C-terminal region, which contains both SEMG1 and anti-EPPIN antibody 
interacting surfaces (O’Rand et al, 2004; Silva; Hamil, Richardson, & O’Rand, 2012). 
Figure 1A illustrates the EPPIN C-terminal docking site for SEMG1 and C-terminal anti-
EPPIN antibodies. Utilizing EPPIN’s Y107-F117 loop, which had been shown previously to 
be the critical site for SEMG1 binding (Silva, Hamil, Richardson, & O’Rand, 2012), and the 
E2Q peptide, the ClusPro2 docking models were evaluated. The docking results allowed us 
to map the amino acid residues of EPPIN that bind to the E2Q peptide. Figures 1B, 1C 
illustrate one interaction model containing the peptide in the Y107-F117 binding loop. 
Examination of the model (Pettersen et al. 2004) revealed 8 apparent H-bonds between 
EPPIN and E2Q in the binding site. Information from SEMG1 peptide binding indicated that 
the compound should cover a surface area of approximately 8.9 × 6.5Å of the binding site, a 
relatively large area, although not unexpected for a protein-protein interaction site. We 
found that the EPPIN residues shown in Table 1 bind specific SEMG1 peptide residues. 
These EPPIN residues (Y107, N113, N114, N116, Q118, and K120; Table 1) are most likely 
the critical ones that our lead compound should interact with in order to inhibit sperm 
motility.
Subsequent experiments with potential contraceptive compounds found this to be the case. 
As shown in Figure 2 and Table 2, the test compounds B4, B41, B42, and B4_R1 exhibit 
various inhibition values (IC50) in all three assays; primary, which assays EPPIN-anti-
EPPIN antibody binding (S21C; O’Rand, Widgren, Hamil, Silva, & Richardson, 2011), 
secondary, which assays EPPIN-SEMG1 binding, and live cell (CASA), which assays 
human sperm motility (O’Rand, Widgren, Hamil, Silva, & Richardson, 2011). Compound 
B4 has a sperm motility IC50 of 11.4 μM and forms H-bonds with EPPIN amino acids 
Y107, N114 and N116 in our docking studies using the SwissDock platform (Grosdidier, 
Zoete, & Michielin, 2011). Compounds B41 and B42 form fewer H-bonds in the binding 
pocket and are comparatively less effective in inhibiting sperm motility, while B4-R1 is 
completely outside the pocket and has no effect on sperm motility. These examples 
demonstrate that our methodology for identifying contraceptive compounds is effective.
8. Prospects for Success
Men have two choices for contraception, the condom and vasectomy. The disadvantages of 
condoms and vasectomies are that vasectomies are not readily reversible and condoms have 
a high typical use failure rate (Contraceptive Use in the United States, Guttmacher Institute, 
2015). Nevertheless, one in three married couples in Australia and New Zealand rely on 
vasectomy for their contraception, one in six in the United States, and one in twenty 
worldwide (Sneyd, Cox, Paul, & Skegg, 2001). Condoms account for an additional 13% of 
contraceptive use in developed countries. In a study of British men, 80% placed a 
hypothetical male pill as one of their top three contraceptive choices (Brooks, 1998) and 
over 60% of men in Germany, Spain, Brazil and Mexico were willing to use a new method 
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of male contraception (Heinemann, Saad, Wiesemes, White, & Heinemann, 2005). In 1970 
only 15% of men who were fathering children were over the age of 35, today it is 25%. This 
increase in time before a man chooses to become a father demonstrates a need for a new, 
reliable and reversible means of male contraception. Consequently a new contraceptive for 
men has a good chance of success in the market. In spite of the need, whether or not any of 
the new therapeutic agents in the pipeline for male contraception will actually make it to the 
market cannot be determined at this time. Although the obstacles are numerous, establishing 
long-term safety and in vivo efficacy, the goal of bringing a new male contraceptive to 
market will not be met without increased funding and pharmaceutical expertise. 
Nevertheless, we remain optimistic toward a positive outcome.
Abbreviations
Amino Acids
Y tyrosine
Q glutamine
N asparagine
H histidine
E glutamic acid
S serine
K lysine
V valine
T threonine
L leucine
C cysteine
P proline
A alanine
D aspartic acid
CAS CRISPER-associated genes
CASA computer-assisted sperm analysis
IC50 inhibitor concentration at 50% level
VSL the average velocity measured in a straight line from the beginning to the end of 
the sperm track in μm/sec
RMI relative motility inhibition
PSA prostate specific antigen
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Figure 1. 
(A) 3D model of the EPPIN C-terminal with the SEMG1 binding sequence shown in blue. 
Three of EPPIN’s key amino acids within the binding site are indicated by the arrows: 
Y107, Q118 and N116.
(B) The SEMG1 peptide E2Q (red) binding to the EPPIN C-terminal. Green lines indicate 
H-bonds. Not all the EPPIN-E2Q H-bonds are visible in this view. Q7 and H2 are E2Q 
amino acids, see Table 1
(C) The SEMG1 peptide E2Q (red) binding to the EPPIN C-terminal shown in surface view 
with the docking pocket indicated in blue.
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Figure 2. Potential Contraceptive Compounds
Four compounds which have been evaluated for their contraceptive potential to bind EPPIN 
and inhibit sperm motility utilizing the assays described in the text. The data are given in 
Table 2.
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Table 1
EPPIN Residue SEMG1 peptide E229-Q247 (1–19) H-bond
Y107 Q7 1.863Å
N113 S3 1.918Å
N114 H2 2.133Å
N116 Q7 1.966Å
Q118 S9
V6
Q15
2.093Å
2.05Å
2.091Å
K120 Q15 1.948Å
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Table 2
Assays to Evaluate Potential Contraceptive Compound Function
Compound Name B4 B41 B42 B4_R1
Compound Screen
Primary1 17.6 +/− 7.8
n=10
15.4 +/− 8.5
n=3
18.9 +/− 16.0
n=3
258
n=1
Secondary1 11.5 +/− 2.3
n=10
10.0 +/− 2.5
n=3
9.5 +/− 1.8
n=3
No activity
Live cell1 (CASA) 11.4 +/− 3.9
n=3
73.5 +/− 20.5
n=2
37.0 +/− 11.3
n=2
No effect
H-Bonds to EPPIN2 Y107
N114
N116
Q118
N122
N116 D96
K98
1
IC50 values (μM) for each screen (see text for description)
2
EPPIN amino acid residues to which the compound formed H-bonds
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